Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Shares

Representative Lisa C. McClain (R-Michigan) recently bought shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of ACI Worldwide (NASDAQ:ACIW) on 8/19/2025.
• Purchased $1,001 – $15,000 in shares of HCA Healthcare (NYSE:HCA) on 8/19/2025.
• Sold $1,001 – $15,000 in shares of Amedisys (NASDAQ:AMED) on 8/18/2025.
• Purchased $1,001 – $15,000 in shares of Kite Realty Group Trust (NYSE:KRG) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of US Foods (NYSE:USFD) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 8/13/2025.

GSK Stock Down 0.6%

Shares of NYSE:GSK opened at $40.04 on Wednesday. The business’s 50 day moving average is $38.81 and its 200 day moving average is $38.50. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $43.14. The stock has a market cap of $81.55 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 2.01 and a beta of 0.53.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $7.92 billion. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The business’s revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK’s payout ratio is presently 77.78%.

Hedge Funds Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. Twin Peaks Wealth Advisors LLC purchased a new stake in GSK during the second quarter valued at approximately $25,000. HHM Wealth Advisors LLC grew its stake in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 460 shares during the last quarter. Costello Asset Management INC bought a new position in shares of GSK during the first quarter valued at approximately $31,000. SOA Wealth Advisors LLC. grew its stake in GSK by 252.1% in the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 605 shares in the last quarter. Finally, Richardson Financial Services Inc. grew its stake in GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 472 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Berenberg Bank reiterated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GSK has a consensus rating of “Reduce” and an average target price of $37.38.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.